Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (NASDAQ: CSTL), a healthcare company focused on innovative diagnostic testing, has announced its participation in the upcoming 2025 Jefferies Global Healthcare Conference. The company's executive management will deliver a corporate presentation on Wednesday, June 4, 2025, at 7:35 a.m. Eastern time. Investors and interested parties can access the live audio webcast through Castle Biosciences' investor relations website, with a replay available after the presentation.
Castle Biosciences (NASDAQ: CSTL) presented new data validating their DecisionDx-UM test and PRAME biomarker for uveal melanoma (UM) at the ARVO 2025 Annual Meeting. The study analyzed a real-world cohort of 1,297 patients with UM, validating findings from the COOG2.1 study.
The research confirms that combining PRAME gene expression information with DecisionDx-UM test results can better predict metastatic risk in UM patients. The study utilized data from the National Cancer Institute's SEER Program, demonstrating that co-reporting DecisionDx-UM class and PRAME status provides enhanced insights into metastasis likelihood, enabling more personalized treatment strategies for this rare but aggressive eye cancer.
Castle Biosciences (NASDAQ: CSTL) is commemorating Skin Cancer Awareness Month in May 2025 through various initiatives and partnerships. The company is sponsoring IMPACT Melanoma's virtual patient symposium "Melanoma Diagnosis: A Toolkit to Support the Journey" on May 21, featuring Dr. Aaron Farberg. Castle is also highlighting melanoma survivor Leah Adams' story, who benefited from their DecisionDx-Melanoma test for recurrence risk assessment.
The company continues partnerships with IMPACT Melanoma, AIM at Melanoma, and Melanoma Research Foundation, participating in advocacy walks nationwide. Additionally, Castle will be featured in USA TODAY's 2025 Skin Health Campaign, with an article titled "Transforming Skin Cancer and Melanoma Outcomes" appearing in the May 30 edition.
Castle Biosciences (Nasdaq: CSTL) has published a new study showing their DecisionDx-Melanoma test surpasses both AJCC staging and CP-GEP in identifying low-risk melanoma patients. The test achieved a 2.8% sentinel lymph node positivity rate, significantly below the NCCN guidelines' 5% threshold for avoiding sentinel lymph node biopsy (SLNB) surgery.
The study, published in Cancer Diagnosis & Prognosis, analyzed T1-T2 melanoma tumors across multiple validation studies. While patients classified as low risk by CP-GEP showed a 6.2% SLN positivity rate, DecisionDx-Melanoma demonstrated superior performance at 2.8%. This improvement is particularly significant as over 90% of T1-T2 tumor patients who undergo SLNB receive negative results.
The findings support using DecisionDx-Melanoma to guide SLNB decisions, especially for patients with thin tumors where surgical complications may outweigh benefits. The test provides personalized risk assessment for sentinel lymph node positivity and recurrence, enabling more informed melanoma management decisions.